Inderjit Kaul - 22 Dec 2025 Form 4 Insider Report for Minerva Neurosciences, Inc. (NERV)

Role: Director
Signature: /s/ Geoff Race, Attorney-in-Fact
Issuer symbol: NERV
Transactions as of: 22 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 23 Dec 2025, 16:15:21 UTC
Previous filing: 18 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kaul Inderjit	Director	C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON	/s/ Geoff Race, Attorney-in-Fact	23 Dec 2025	0002095703

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NERV	Stock Option (right to buy)	Award	$0	+364,504		$0.000000	364,504	22 Dec 2025	Common Stock	364,504	$3.98	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.

Content

25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.